跳轉至內容
Merck
全部照片(2)

文件

M1559

Sigma-Aldrich

Moxonidine hydrochloride

≥98%

同義詞:

4-Chloro-6-methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine hydrochloride, BDF-5895

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C9H12ClN5O · HCl
CAS號碼:
分子量::
278.14
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

化驗

≥98%

起源

Solvay

SMILES 字串

Cl.COc1nc(C)nc(Cl)c1NC2=NCCN2

InChI

1S/C9H12ClN5O.ClH/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9;/h3-4H2,1-2H3,(H2,11,12,15);1H

InChI 密鑰

ZZPAWQYZQVUVHX-UHFFFAOYSA-N

應用

Moxonidine hydrochloride has been used:
  • as a standard to study its blood-brain barrier (BBB) permeability in porcine brain lipid extract by parallel artificial membrane permeability assay (PAMPA) method
  • as a standard to study the chromatographic behavior and lipophilicity by reversed-phase thin-layer chromatography (RP-TLC)
  • as an imidazoline I1 receptor agonist to study its effects on excitatory inputs in airway vagal preganglionic neuron (AVPN)

生化/生理作用

Moxonidine is a selective high-affinity imidazoline I1-receptor agonist and a selectively low-affinity α2-adrenoceptor agonist. It exhibits anti-hypertensive properties by reducing blood pressure efficiently. Moxonidine also exhibits spinal analgesic activity through the α2C-adrenoceptor component.

特點和優勢

This compound is featured on the Imidazoline Binding Sites page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Solvay. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Estimation of lipophilicity and retention behavior of some alpha adrenergic and imidazoline receptor ligands using RP-TLC
Mohamed S, et al.
Journal of Liquid Chromatography and Related Technologies, 37(20), 2829-2845 (2014)
Xujiao Zhou et al.
Brain research, 1732, 146695-146695 (2020-02-03)
As an imidazoline I1 receptor agonist with very weak binding affinity for α2-adrenoceptors, moxonidine is commonly used in the treatment of hypertension. Moxonidine also has been implicated to act centrally to reduce airway vagal outflow. However, it is unknown at
Jelica Vucicevic et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 68, 94-105 (2014-12-30)
Imidazoline receptor ligands are a numerous family of biologically active compounds known to produce central hypotensive effect by interaction with both α2-adrenoreceptors (α2-AR) and imidazoline receptors (IRs). Recent hypotheses connect those ligands with several neurological disorders. Therefore some IRs ligands
Caroline Fenton et al.
Drugs, 66(4), 477-496 (2006-04-07)
Moxonidine (Physiotens, Moxon, Cynt) is an orally administered imidazoline compound with selective agonist activity at imidazoline I1 receptors and only minor activity at alpha2-adrenoceptors. Moxonidine acts centrally to reduce peripheral sympathetic activity, thus decreasing peripheral vascular resistance. In patients with
C Bing et al.
British journal of pharmacology, 127(1), 35-42 (1999-06-16)
The antihypertensive agent moxonidine, an imidazoline Ii-receptor agonist, also induces hypophagia and lowers body weight in the obese spontaneously hypertensive rat, but the central mediation of this action and the neuronal pathways that moxonidine may interact with are not known.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務